Articles

In vitro chromosomal aberration test (OECD 473): detecting clastogens

5 min read

Genes are not the only place genotoxic damage shows up. Sometimes a compound leaves the DNA sequence intact but breaks or rearranges whole stretches of chromosome — a mechanism called clastogenicity. The most direct way to see it is to look at the chromosomes themselves, under the microscope, at the moment they are most visible: metaphase. That is exactly what the in vitro chromosomal aberration test (OECD 473) does.

It is one of the classic pillars of the genotoxicity battery, sitting alongside the Ames test (gene mutations) and the micronucleus test. This article explains what it detects, how it is run, and how to decide between it and the micronucleus assay for the “chromosomal damage” slot of your battery.

Key points

What it detects

Structural chromosomal aberrations — breaks, deletions, exchanges, dicentrics and rings — i.e. clastogenic damage.

How

Cells are arrested in metaphase, spread, stained and scored chromosome by chromosome.

With and without S9

Run ±metabolic activation to catch both direct-acting clastogens and those needing bioactivation.

Battery role

An accepted in vitro cytogenetic test under ICH S2(R1) — interchangeable with the in vitro micronucleus test.

What the test actually detects

The chromosomal aberration test scores structural changes to chromosomes that arise when DNA breakage is misrepaired or left unrepaired before cell division. Trained cytogeneticists classify what they see, including:

  • Chromatid- and chromosome-type breaks — discontinuities in one or both sister chromatids;
  • Exchanges — rearrangements such as dicentrics, rings and translocations;
  • Deletions and acentric fragments — lost pieces of chromosome.

The assay can also flag polyploidy and endoreduplication, which can signal effects on the cell-division apparatus — though for numerical/aneugenic events the micronucleus test is the more suitable tool.

At a glance

OECD 473

The in vitro mammalian chromosomal aberration test guideline

±S9

Tested with and without rat-liver metabolic activation

≥300

Metaphases typically scored per concentration for statistical power

Metaphase

The stage at which chromosomes condense and become individually visible

How the assay is run

Established mammalian cell systems are used — Chinese hamster lines (CHO, CHL, V79), human TK6 cells, or primary human peripheral blood lymphocytes. The workflow is:

  • Treatment — cells are exposed to the test item across a range of concentrations, with and without S9, over short and extended treatment schedules.
  • Metaphase arrest — a spindle inhibitor (e.g. colcemid) holds dividing cells in metaphase.
  • Harvest and spreading — cells are swollen, fixed and dropped onto slides so the chromosomes spread out.
  • Staining and scoring — slides are stained (e.g. Giemsa) and metaphases are examined and scored for aberrations, alongside a cytotoxicity measure to keep results biologically meaningful.

Chromosomal aberration or micronucleus? Choosing the battery slot

Regulators accept either the chromosomal aberration test or the in vitro micronucleus test (OECD 487) to cover chromosomal damage in the standard battery. They are not identical, though:

  • The chromosomal aberration test provides mechanistic detail — the specific type of aberration — which is valuable when characterising a clastogen.
  • The micronucleus test is faster and higher-throughput, can be automated, and additionally detects aneugens (whole-chromosome loss), which the aberration test does not reliably capture.

In practice, many programmes default to the micronucleus test for throughput and aneugen coverage, and turn to the chromosomal aberration test when a detailed clastogenicity characterisation is needed.

Where it fits in the regulatory battery

Under ICH S2(R1), the standard genotoxicity battery pairs a bacterial gene-mutation test (Ames, OECD 471) with an in vitro test for chromosomal damage — either OECD 473 or OECD 487 — and, where required, in vivo confirmation. Note that OECD 473 is the in vitro method; the corresponding in vivo cytogenetic assessment is usually the bone-marrow micronucleus or chromosomal aberration test.

Frequently asked questions

What does the chromosomal aberration test detect?

It detects structural chromosomal aberrations — breaks, deletions, exchanges, dicentrics and rings — caused by clastogenic agents. It can also flag polyploidy, though it is not the preferred assay for aneugens.

What is the difference between the chromosomal aberration test and the micronucleus test?

The chromosomal aberration test visualises and classifies specific aberrations in metaphase, giving mechanistic detail. The micronucleus test is faster, can be automated, and also detects aneugens (whole-chromosome loss). Regulators accept either for the chromosomal-damage slot of the battery.

Why is the test run with and without S9?

Some compounds are only clastogenic after metabolic activation. Adding an S9 rat-liver fraction simulates mammalian metabolism, so the assay catches both direct-acting clastogens and those that require bioactivation.

Is OECD 473 an in vitro or in vivo test?

OECD 473 is an in vitro test using cultured mammalian cells. In vivo chromosomal damage is assessed separately, typically via the bone-marrow micronucleus or chromosomal aberration test.

Work with our cytogenetics team

GenEvolutioN runs the in vitro chromosomal aberration test under GLP, with experienced cytogeneticists and a full genotoxicity battery around it. Whether you need the aberration test for detailed clastogenicity characterisation or the micronucleus test for throughput, we help you choose and design the right study.

Compare it with the micronucleus test, revisit the genotoxicity fundamentals, or talk to our team.